Literature DB >> 27001482

Cutaneous T-cell Lymphoma and Pruritus: The Expression of IL-31 and its Receptors in the Skin.

Leigh A Nattkemper1, Maria-Estela Martinez-Escala, Ari B Gelman, Elisha M Singer, Alain H Rook, Joan Guitart, Gil Yosipovitch.   

Abstract

Approximately 88% of cutaneous T-cell lymphoma (CTCL) patients are affected by pruritus that responds poorly to current antipruritic therapies. Interleukin (IL)-31, a Th2 cytokine, has been found to be increased in the serum of CTCL patients and to correlate with itch severity. This study investigated the role of IL-31 and its receptors (IL-31 receptor-alpha [IL-31RA] and OSMRβ) in the skin of CTCL patients with mild versus moderate/severe pruritus. Expression levels of IL-31, IL-31RA, and OSMRβ in the skin were measured using immunohistochemistry and correlated to pruritus severity and disease stage. In CTCL patients with moderate/severe pruritus, IL-31 was significantly elevated in the epidermis and dermal infiltrate, while IL-31RA and OSMRβ were significantly elevated only in the epidermis. Furthermore, epidermal IL-31 levels correlated to itch severity. These results show that IL-31 may play a role in CTCL pruritus by exerting indirect effects on sensory nerves through epidermal neoplastic T cells and keratinocytes to transmit itch.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27001482     DOI: 10.2340/00015555-2417

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  32 in total

Review 1.  [New treatment options for chronic pruritus].

Authors:  C Zeidler; B Pfleiderer; S Ständer
Journal:  Hautarzt       Date:  2016-08       Impact factor: 0.751

2.  Itch in dermatomyositis: the role of increased skin interleukin-31.

Authors:  H J Kim; M Zeidi; D Bonciani; S M Pena; J Tiao; S Sahu; V P Werth
Journal:  Br J Dermatol       Date:  2018-06-21       Impact factor: 9.302

Review 3.  IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Micah Belzberg; Madan M Kwatra; Shawn G Kwatra
Journal:  Drugs       Date:  2021-04-21       Impact factor: 9.546

Review 4.  Cutaneous T cell lymphoma.

Authors:  Reinhard Dummer; Maarten H Vermeer; Julia J Scarisbrick; Youn H Kim; Connor Stonesifer; Cornelis P Tensen; Larisa J Geskin; Pietro Quaglino; Egle Ramelyte
Journal:  Nat Rev Dis Primers       Date:  2021-08-26       Impact factor: 52.329

Review 5.  IL-31: State of the Art for an Inflammation-Oriented Interleukin.

Authors:  Francesco Borgia; Paolo Custurone; Federica Li Pomi; Raffaele Cordiano; Clara Alessandrello; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

Review 6.  Peripheral and Central Mechanisms of Itch.

Authors:  Xintong Dong; Xinzhong Dong
Journal:  Neuron       Date:  2018-05-02       Impact factor: 17.173

7.  Correlation of IL-31 gene polymorphisms with susceptibility and clinical recurrence of bladder cancer.

Authors:  Qin Li; Tielong Tang; Peng Zhang; Chenlu Liu; Yan Pu; Yan Zhang; Huizi Song; Yanyun Wang; Yaping Song; Min Su; Bin Zhou; Lin Zhang
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

Review 8.  Physiology and Pathophysiology of Itch.

Authors:  Ferda Cevikbas; Ethan A Lerner
Journal:  Physiol Rev       Date:  2019-12-23       Impact factor: 37.312

9.  Interleukin-31, a Potent Pruritus-Inducing Cytokine and Its Role in Inflammatory Disease and in the Tumor Microenvironment.

Authors:  Alain H Rook; Kathryn A Rook; Daniel J Lewis
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 10.  IL-31, itch and hematological malignancies.

Authors:  Eleonora Di Salvo; Alessandro Allegra; Marco Casciaro; Sebastiano Gangemi
Journal:  Clin Mol Allergy       Date:  2021-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.